Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
- First Online:
- 670 Downloads
The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours’ (NETs) treatment.
Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiated NETs, 27 had well-differentiated NETs in progression after somatostatin analogues. Patients received oxaliplatin e.v. 130 mg/mq i.v. and capecitabine 2,000 mg/mq/die. The primary sites of the disease were: lung (10 pts), pancreas (15 pts), small bowel (8 pts), unknown (1 pt), others (6 pts).
In 13 pts with poorly differentiated NETs objective responses (OR) were: 3 PR (23%), 1 SD (7%), 9 PD (70%). Biochemical responses were 11%. In 27 patients with well-differentiated NETs the OR were: 8 PR (30%), 13 SD (48%) and 6 PD (22%). Biochemical and symptomatic responses were 20 and 50%, respectively.
The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues.
KeywordsCapecitabine Chemotherapy Neuroendocrine tumours Oxaliplatin XELOX
- 1.Solcia E, Kloppel G, Sobin LH (2000) Histologic typing of endocrine tumours. WHO international histological classification of tumours. Springer, Berlin Heidelberg New YorkGoogle Scholar
- 2.Travis WD, Brambilla E, Muller-Hermelink HK, Harris SL (2004) Pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press, GenevaGoogle Scholar
- 9.Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E (2002) Efficacy of chemotherapy combinations for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13:614–621PubMedCrossRefGoogle Scholar
- 14.World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO offset publication N. 48, GenevaGoogle Scholar
- 19.Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 22:4897–4904CrossRefGoogle Scholar
- 20.Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P (1995) A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) group. Ann Oncol 6:77–79PubMedGoogle Scholar